Pari Pharma said this week that its Lamira nebulizer won approval from the FDA to deliver Insmed’s Arikayce amikacin liposome inhalation suspension for the treatment of MAC lung disease.
The company’s Lamira drug-device combination product is intended to be used as part of a combination antibacterial drug regimen for adult patients with limited or no alternative options for treatment, according to Pari Pharma.
Pari Pharma’s platform of nebulizers is based on the company’s eFlow technology, which features a vibrating, perforated membrane designed to improve upper and lower respiratory tract deposition.
Insmed’s Arikayce is the first FDA-approved inhaled liposomal suspension to be aerosolized using a vibrating membrane nebulizer, the company noted.
“Lamira is another great example of an eFlow Technology nebulizer which we optimized for the administration of a specific drug formulation, indicating the strong capabilities of the eFlow Technology platform,” Martin Knoch, president of Pari Pharma said in prepared remarks. “It is rewarding to bring, in close collaboration with the team at Insmed, such technical advancements into the hands of patients with little to no alternative treatment options.”
Insmed’s Pulmovance liposomal technology is designed to boost the delivery of drugs directly to the lungs. There, the drugs are taken up by lung macrophages. This technique helps to prolong the release of drug in the lungs while avoiding the risks associated with systemic drug exposure, Pari Pharma explained.
